NCCN guidelines [4] recently changed to establish adjuvant anti-PD-L1 immunotherapy (atezolizumab) after chemotherapy as the standard of care for stages 2/3A NSCLC patients with PD-L1 > 1%, following the FDA approval [8]. Here, CD274 is linked to non-small cell lung carcinoma.